Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros


Bases de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Int Arch Allergy Immunol ; 116(1): 60-6, 1998 May.
Artigo em Inglês | MEDLINE | ID: mdl-9623511

RESUMO

A group of 9 Mexican lepromatous leprosy patients was studied at the beginning of a type II reaction (erythema nodosum leprosum, ENL) and after 1 or 2 months of thalidomide treatment. ENL patients at the onset of the reaction had slightly higher amounts of anti-Mycobacterium leprae IgG1 and IgG2 antibodies, compared to similar lepromatous patients that did not develop ENL. Neither these antibody levels nor IgM and the other IgG subclasses were importantly modified after thalidomide treatment. Serum TNF was significantly higher in the patients that developed ENL compared to those that did not develop the reaction. TNF levels were slightly decreased after 1 month of thalidomide treatment and significantly decreased after 2 months of treatment. Serum IFN-gamma was significantly lower in patients at the onset of ENL and was increased after 1 and 2 months of thalidomide treatment.


Assuntos
Anticorpos Antibacterianos/classificação , Eritema Nodoso/induzido quimicamente , Imunoglobulina G/sangue , Imunoglobulina G/classificação , Interferon gama/metabolismo , Hansenostáticos/uso terapêutico , Hanseníase Virchowiana/tratamento farmacológico , Talidomida/uso terapêutico , Fator de Necrose Tumoral alfa/metabolismo , Adolescente , Adulto , Idoso , Anticorpos Antibacterianos/sangue , Interpretação Estatística de Dados , Feminino , Humanos , Imunoglobulina M/sangue , Imunoglobulina M/classificação , Interferon gama/sangue , Hansenostáticos/administração & dosagem , Hansenostáticos/efeitos adversos , Hanseníase Dimorfa/sangue , Hanseníase Dimorfa/tratamento farmacológico , Hanseníase Virchowiana/metabolismo , Hanseníase Tuberculoide/sangue , Hanseníase Tuberculoide/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Mycobacterium leprae/imunologia , Talidomida/administração & dosagem , Talidomida/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA